News

July has seen one very positive development in the faltering attempts by Europe's governments to resolve that challenge of providing patients with innovative medicines without bankrupting health budgets.

CBI Conference Producer, Trevor Sosvielle, recently sat down with Matthew Amsden, CEO of ProofPilot to discuss his early work in HIV prevention trials. Amsden shares how these experiences helped shape ProofPilot and its patient-centric clinical trial approach.

James Man considers the practical measures firms can take to embed the patient perspective more directly into their R&D planning.

The question is, how much attention should be paid to historical recruitment figures if the team only reviews the data from one (or two) similar studies?

Updated employee announcements, business news, awards, and recognition in the industry today.

In this interview, Jim Streeter, Global Vice President of Life Sciences Product Strategy at Oracle, will elaborate further on Oracle’s strategy with mHealth in clinical trials.

The British government has at last set out its ambitions for cooperation on medicines post-Brexit.

The potential for innovative gene therapies to treat and even cure a range of serious diseases is prompting FDA to ramp up support for developing and testing new products efficiently and effectively.

Given the rapid changes in the communication landscape brought about by participative Internet use and social media, it is important to develop a better understanding of these technologies and their impact on health communication.

Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don’t have and squanders valuable resources.